chemical structure of etavopivat

oral pyruvate kinase activator

in Ph. II/III for genetic anemias

200 or 400 mg QD, follows etavopivat

J Pharmacol Exp Ther

Forma Therapeutics, Watertown, MA

Context. Etavopivat (Forma Therapeutics) is an oral erythrocyte pyruvate kinase activator being developed for sickle cell diseaseand other hemoglobinopathies, previously reported in 2019. Hydroxyurea had been the only approved…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.